Literature DB >> 3021037

Elevated serum chromogranin A concentrations in small-cell lung carcinoma.

R E Sobol, D T O'Connor, J Addison, K Suchocki, I Royston, L J Deftos.   

Abstract

Serum chromogranin A concentrations measured by radioimmunoassay in patients with small-cell lung carcinoma were compared with values from healthy adults and patients with non-small-cell lung carcinoma or chronic obstructive pulmonary disease. The mean (+/- SE) level was significantly higher (p less than or equal to 0.02) in patients with small-cell lung carcinoma (815 +/- 290 ng/mL, n = 46) than in normal controls (123 +/- 6 ng/mL, n = 20) or patients with chronic obstructive pulmonary disease (169 +/- 18 ng/mL, n = 39), lung adenocarcinoma (180 +/- 22, ng/mL, n = 62), large-cell lung carcinoma (183 +/- 23 ng/mL, n = 18), or lung epidermoid carcinoma (203 +/- 37 ng/mL, n = 78). The mean concentration in extensive-stage small-cell lung carcinoma (1155 +/- 449 ng/mL, n = 29) was significantly greater (p = 0.026) than in limited disease (234 +/- 56 ng/mL, n = 17). Elevated serum chromogranin A values were seen in 53% of patients with limited and 72% with extensive disease. Four patients originally classified as having non-small-cell lung carcinomas with raised chromogranin A levels were subsequently found to have mixed small-cell and non-small-cell tumors. Serum chromogranin A concentrations may be a useful marker of small-cell lung carcinoma disease activity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3021037     DOI: 10.7326/0003-4819-105-5-698

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  14 in total

1.  Q RT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease.

Authors:  Mark Kidd; Irvin M Modlin; Shrikant M Mane; Robert L Camp; Michael D Shapiro
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

2.  Undegraded chromogranin A is present in serum and enters the endocytotic lysosomal pathway in kidney.

Authors:  R Weiler; H J Steiner; R Fischer-Colbrie; K W Schmid; H Winkler
Journal:  Histochemistry       Date:  1991

Review 3.  Neuroendocrine differentiation in lung carcinoma.

Authors:  B J Addis
Journal:  Thorax       Date:  1995-02       Impact factor: 9.139

4.  Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits.

Authors:  Aldo Spadaro; Antonino Ajello; Carmela Morace; Agata Zirilli; Graziella D'arrigo; Carmelo Luigiano; Francesco Martino; Anna Bene; Domenico Migliorato; Santi Turiano; Oscar Ferraù; Maria-Antonietta Freni
Journal:  World J Gastroenterol       Date:  2005-04-07       Impact factor: 5.742

5.  Chromogranin A expression in normal and malignant human tissues.

Authors:  L J Helman; A F Gazdar; J G Park; P S Cohen; J D Cotelingam; M A Israel
Journal:  J Clin Invest       Date:  1988-08       Impact factor: 14.808

Review 6.  Glycosylated Chromogranin A: Potential Role in the Pathogenesis of Heart Failure.

Authors:  Anett H Ottesen; Geir Christensen; Torbjørn Omland; Helge Røsjø
Journal:  Curr Heart Fail Rep       Date:  2017-12

7.  Increased levels of bombesin-like peptides in the lower respiratory tract of asymptomatic cigarette smokers.

Authors:  S M Aguayo; M A Kane; T E King; M I Schwarz; L Grauer; Y E Miller
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

8.  Chromogranin A, a significant prognostic factor in small cell lung cancer.

Authors:  L Drivsholm; L I Paloheimo; K Osterlind
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

9.  Characterisation of circulating chromogranin A in human cancer patients.

Authors:  A Corti; A Gasparri; F X Chen; M Pelagi; A Brandazza; A Sidoli; A G Siccardi
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

10.  Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer.

Authors:  P W Johnson; S P Joel; S Love; M Butcher; M R Pandian; L Squires; P F Wrigley; M L Slevin
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.